Anzupgo (Delgocitinib) FDA Approval for Eczema Treatment
Anzupgo: A New Topical Treatment for Chronic Hand eczema Shows Promising Results
Table of Contents
A new topical treatment, Anzupgo (delgocitinib), is showing notable promise in managing moderate to severe chronic hand eczema, offering relief from debilitating symptoms like itching and pain. Developed by Leo Pharma, Anzupgo is a Janus kinase (JAK) inhibitor cream that has demonstrated notable efficacy in clinical trials, possibly transforming the daily lives of individuals struggling with this persistent condition.
How Anzupgo Works and Its Efficacy
Anzupgo is a topical cream formulated with 20 milligrams (mg) of delgocitinib per gram. It belongs to the class of JAK inhibitors, which work by targeting specific pathways involved in inflammation and immune responses. By inhibiting these pathways, Anzupgo aims to reduce the underlying inflammation that drives chronic hand eczema.The efficacy of Anzupgo was evaluated in two pivotal clinical trials, DELTA 1 and DELTA 2, which collectively involved nearly 1,000 adults diagnosed with moderate to severe chronic hand eczema. Participants in these studies applied either Anzupgo or a non-medicated placebo cream twice daily for a period of 16 weeks.
The results from these trials were encouraging:
DELTA 1: In this study, 20 percent of participants who used Anzupgo achieved “clear” or “almost clear” skin. This is a significant enhancement compared to the 10 percent of participants who used the placebo cream.
DELTA 2: The success rate was even higher in DELTA 2, with 29 percent of Anzupgo users reaching “clear” or “almost clear” skin, compared to only 7 percent in the placebo group.
Beyond visible skin improvement, Anzupgo also demonstrated a substantial impact on the quality of life for patients by significantly reducing itch and pain. By week 16, nearly half of the Anzupgo users reported a four-point or greater drop in both itch and pain symptom scores.
Impact on Daily Life
The reduction in pain and itch offered by Anzupgo can have a profound effect on daily activities. A significant drop in pain scores can transform constant, disruptive discomfort into barely noticeable symptoms. This relief can empower individuals to:
Work with their hands: Tasks that were previously painful or unfeasible due to eczema can become manageable.
Sleep more soundly: Chronic itching and pain often disrupt sleep patterns. Alleviating these symptoms can lead to more restful nights.
Perform daily tasks better: From household chores to personal care, improved symptom control can enhance overall functionality and independence.
Similarly, improvements in chronic itching translate directly into better concentration, rest, and mental well-being.A four-point reduction in itch intensity often signifies a shift from an unbearable sensation to one that is manageable or has disappeared entirely,contributing to improved focus and emotional resilience.
Safety and Side Effects of Anzupgo
The safety profile of Anzupgo in clinical studies was found to be comparable to that of the placebo. The most commonly reported side effects included:
Application-site reactions: These can manifest as pain, itching, skin discoloration, or tingling at the site were the cream was applied.
Mild skin infections: Instances of mild infections such as paronychia (infection around the fingernail or toenail) or cellulitis (bacterial skin infection) were observed.
Low white blood cell count: A decrease in white blood cells was also noted as a potential side effect.
Anzupgo is classified as a JAK inhibitor.While this class of drugs is effective in managing inflammatory conditions, it’s important to note that JAK inhibitors, whether oral or topical, can potentially lower the immune system’s ability to fight infections.Some individuals taking oral JAK medications have experienced serious infections requiring hospitalization or have even died from infections. However, unlike oral JAK medications, Anzupgo cream does not carry a black box warning regarding potentially serious side effects.
The approved usage for Anzupgo is a 2 percent formulation, with a maximum application of 30 grams (g) over a two-week period or 60 g per month.
Important Considerations for JAK Inhibitors
patients considering Anzupgo, or any JAK inhibitor, should discuss potential risks and benefits thoroughly with their healthcare provider. Understanding the potential for increased susceptibility to infections is crucial, and prompt medical attention should be sought for any signs of infection.